ClinicalTrials.gg
Sign In
BiologicalDrug

SAR-439459 clinical trials

Also written SAR439459.

studies test it
3
open now
0
in phase 3
0
first study started
2017

How each study uses SAR-439459 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

SAR439459
3

Studies by the year they started

3 studies that test it; most in 2017 (1)

Studies that test SAR-439459, by start year
YearStudies
20171
20211
20221

By phase

A phase 1/2 study counts in both.

Phase 1
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Osteogenesis Imperfecta
1

Who runs them

Industry 2 · Other 1

Sanofi (2) · M.D. Anderson Cancer Center (1)

Studies

Open first, then newest update. How each study uses SAR-439459 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 3

Given beside what is tested · 1 — SAR-439459 is usual care or a partner of the new treatment

Codes

What other systems call SAR-439459 · ClinicalTrials.gg INT015463

  • UNII (FDA) 7EFI23P78RSAR-439459One source FDA
  • NCI Thesaurus C146862Anti-TGF-beta Monoclonal Antibody SAR-439459One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.